Page 64 - Formulation News Today

Sumitomo Chemical provides high-quality oligonucleotides as drug substance for nucleic acid drugs to various customers. We offer an agile response to your nucleic acid drug discovery and development, based on the same trust and proven technology that we have cultivated in the manufacture of small-molecule API for more than 40 years.

A New Zealand clean label sparkling water brand that uses just two ingredients has expanded distribution to neighbouring Australia as it looks to boost sales.

More time before next week when joe biden is in glasgow, and my belief is that we can resolve all these issues and then with certainty the democrats can vote both for the infrastructure bill, and for joe bidens build back better program with all of the details that are very clear to everyone, not just in the congress, but all across the country. >> it sounds like youre almost granting accepting that this is not going to happen today. >> well, i have not seen any specific legislative text with re...

Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.

11-year-olds vaccinated. there are other parents who will be holding back a little bit and waiting and trying to get more information and talking to their pediatricians, which is certainly what i suggest. talk to your pediatrician, family doctor, health care provider, to get good advice. >> so dr. torres, lets talk about the differences between the way adults were vaccinated and the way that kids will be, both in terms of the shots, the doses, and the places where theyll actually be vaccinated. ...

Scientists in Japan have found a way to 3D-bioprint wagyu beef by assembling muscle fibre, fat fibre and blood vessels into a steak-like structure similar to actual meat.

EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Miscellaneous Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation 26-Oct-2021

EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Miscellaneous Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation 26-Oct-2021 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is so...

Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.

Serious adverse events and very consistent with the hundreds of millions of doses that have been administered in adults in the u.s. as well as outside the u.s. but of course its going to be extremely important to monitor safety, and safety is paramount for all of us, not just children, but also adults. but i think that, you know, we want to make sure that we are looking at this data closely and deliberating before we make a decision. >> in terms of that safety, jim and i were discussing earlier,...